夏云　王志

【摘要】 目的：分析EGFR-TKIs在晚期非小细胞肺癌靶向治疗中所能够取得的治疗效果及预后。方法：选取2014年5月-2016年5月本院收治的非小细胞肺癌患者40例，患者口服EGFR-TKIs进行靶向治疗，治疗1个月后对其治疗效果与毒副作用进行分析。患者既往均进行含铂类方案的周期化疗，平均进行4周期。患者随访时间均超过半年。结果：1例患者口服EGFR-TKIs 36个月，其他患者口服3～19个月；客观缓解率为40.0%，疾病控制率为60.0%；随访截止到2017年10月，患者死亡4例，1年生存率为90.0%（36/40），MST为12个月；其不良反应表现主要有脱皮、肝酶升高、腹泻、皮肤瘙痒等，其中脱皮的发生率较高为32.5%（13/40），肝酶升高为15.0%（6/40），腹泻为12.5%（5/40），皮肤瘙痒为12.5%（5/40）。结论：EGFR-TKIs治疗晚期非小细胞肺癌可促进患者症状的改善，不良反应较少，能够获得比较好的临床获益率，具有重要的临床推广应用价值。

【关键词】 EGFR-TKIs； 晚期非小细胞肺癌； 靶向治疗； 治疗效果； 预后分析

Therapeutic Effect and Prognosis of EGFR-TKIs in Targeted Treatment of Advanced Non-small Cell Lung Cancer/XIA Yun，WANG Zhi.//Medical Innovation of China，2017，14（35）：141-143

【Abstract】 Objective：To analyze the therapeutic effect and prognosis of EGFR-TKIs in target treatment of advanced non-small cell lung cancer.Method：A total of 40 patients with non-small cell lung cancer treated in our hospital from May 2014 to May 2016 were selected.They were treated with EGFR-TKIs for target treatment，after 1 months of treatment，the therapeutic effect and poisonous effects were analyzed.Patients who had previously performed cyclical chemotherapy containing platinum regimens，the average of 4 cycles.They were followed up for more than half a year.Result：1 patient were taken oral EGFR-TKIs for 36 months，and other patients were taken for 3-19 months，the rate of objective remission was 40.0%，and the rate of disease control was 60.0%，by the end of October 2017，4 patients died，1 year survival rate was 90.0%（36/40），and the MST was 12 months.The main adverse reactions were desquamation，elevated liver enzyme，diarrhea，and skin pruritus，et al，the incidence of skin peeling was high，which was 32.5%（13/40），liver enzyme increased was 15.0%（6/40），diarrhea was 12.5%（5/40），and skin pruritus was 12.5%（5/40）.Conclusion：EGFR-TKIs in treatment of advanced non-small cell lung cancer can promote the improvement of symptoms and fewer adverse reactions，can get a good clinical benefit rate，and has important clinical application value.

【Key words】 EGFR-TKIs； Advanced non-small cell lung cancer； Targeted therapy； Therapeutic effect； Prognostic analysis

First-authors address：The First Peoples Hospital of Jiujiang City，Jiujiang 332000，China

doi：10.3969/j.issn.1674-4985.2017.35.039

肺癌是臨床上世界死亡率比较高的肿瘤之一[1-3]。有关数据显示，非小细胞肺癌发生率占所有肺癌的75%～85%，患者发现时候大多为晚期，常采用的治疗方式为化疗，生存期为8～11个月[4-6]。但是治疗效果比较有限，采用生物靶向治疗是一种比较新的治疗方式，能够取得比较理想的治疗效果，在临床上具有重要的应用价值[7-9]。表皮生长因子受体（epithelial growth factor receptor，EGFR）在肺癌治疗过程中是主要的靶点[10]，运用EGFR-酪氨酸激酶抑制剂（tyrosine kinase inhibitors，TKIs）对酪氨酸激酶的活化现象进行有效抑制，能够阻断肿瘤病灶的发展[11]。尽管EGFR-TKIs在非小细胞肺癌患者治疗中取得阳性结果，对于患者预后具有改善作用，但是这种有效性具有一定的针对性，并非全部患者都能起到良好的治疗效果。……